ECSP045145A - Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo - Google Patents

Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo

Info

Publication number
ECSP045145A
ECSP045145A EC2004005145A ECSP045145A ECSP045145A EC SP045145 A ECSP045145 A EC SP045145A EC 2004005145 A EC2004005145 A EC 2004005145A EC SP045145 A ECSP045145 A EC SP045145A EC SP045145 A ECSP045145 A EC SP045145A
Authority
EC
Ecuador
Prior art keywords
inhibitors
norepinefrine
recaptation
cognitive failure
failure treatment
Prior art date
Application number
EC2004005145A
Other languages
English (en)
Spanish (es)
Inventor
Franklin Porter Bymaster
Donald Richard Gehlert
David Lee Mckinzie
Charles Renkin Yang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP045145A publication Critical patent/ECSP045145A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EC2004005145A 2001-12-11 2004-06-09 Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo ECSP045145A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11

Publications (1)

Publication Number Publication Date
ECSP045145A true ECSP045145A (es) 2004-07-23

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005145A ECSP045145A (es) 2001-12-11 2004-06-09 Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo

Country Status (26)

Country Link
US (1) US20050009925A1 (enExample)
EP (1) EP1458368B1 (enExample)
JP (1) JP2005517647A (enExample)
KR (1) KR20040066895A (enExample)
CN (1) CN1713900A (enExample)
AU (1) AU2002352625A1 (enExample)
BR (1) BR0213581A (enExample)
CA (1) CA2467802A1 (enExample)
CO (1) CO5590907A2 (enExample)
CZ (1) CZ2004709A3 (enExample)
DE (1) DE60223718T2 (enExample)
EA (1) EA200400793A1 (enExample)
EC (1) ECSP045145A (enExample)
ES (1) ES2295435T3 (enExample)
HR (1) HRPK20040528B3 (enExample)
HU (1) HUP0402619A3 (enExample)
IL (1) IL161989A0 (enExample)
MX (1) MXPA04005716A (enExample)
MY (1) MY136367A (enExample)
NO (1) NO20042904L (enExample)
NZ (1) NZ532065A (enExample)
PL (1) PL369311A1 (enExample)
SK (1) SK2442004A3 (enExample)
TW (1) TW200300672A (enExample)
WO (1) WO2003049724A1 (enExample)
ZA (1) ZA200404274B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05001705A (es) * 2002-08-14 2005-04-19 Pharmacia & Upjohn Co Llc Uso de reboxetina para el tratamiento de sofocos.
WO2005011583A2 (en) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Treatment of allergic rhinitis and asthma
CA2530014A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
CA2548304A1 (en) * 2003-12-12 2005-07-07 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
GEP20084550B (en) * 2004-04-30 2008-11-25 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317731A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Hyperhidrosis treatment
TW201107485A (en) * 2009-07-31 2011-03-01 Univ Nat Taiwan Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1)
EP2764863B1 (en) * 2011-10-03 2020-03-11 National Center for Geriatrics and Gerontology Tau aggregation inhibitor
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2962687B1 (en) 2013-04-02 2019-06-05 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
EA011094B1 (ru) * 1999-07-01 2008-12-30 Фармация Энд Апджон Компани Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
YU21602A (sh) * 1999-10-13 2005-06-10 Pfizer Products Inc. Derivati biaril etra korisni kao inhibitori ponovnog podizanja monoamina
CA2431041A1 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
AU2002243451A1 (en) * 2001-01-02 2002-07-16 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory

Also Published As

Publication number Publication date
IL161989A0 (en) 2005-11-20
TW200300672A (en) 2003-06-16
HRPK20040528B3 (en) 2006-03-31
HUP0402619A3 (en) 2008-04-28
NO20042904L (no) 2004-09-07
NZ532065A (en) 2007-03-30
DE60223718D1 (de) 2008-01-03
CN1713900A (zh) 2005-12-28
BR0213581A (pt) 2004-08-24
EP1458368A1 (en) 2004-09-22
SK2442004A3 (en) 2004-12-01
PL369311A1 (en) 2005-04-18
HRP20040528A2 (en) 2004-10-31
ES2295435T3 (es) 2008-04-16
CZ2004709A3 (cs) 2004-10-13
ZA200404274B (en) 2005-09-13
CA2467802A1 (en) 2003-06-19
MY136367A (en) 2008-09-30
CO5590907A2 (es) 2005-12-30
US20050009925A1 (en) 2005-01-13
HUP0402619A2 (hu) 2005-03-29
KR20040066895A (ko) 2004-07-27
DE60223718T2 (de) 2008-10-30
JP2005517647A (ja) 2005-06-16
EP1458368B1 (en) 2007-11-21
WO2003049724A1 (en) 2003-06-19
AU2002352625A1 (en) 2003-06-23
MXPA04005716A (es) 2004-12-06
EA200400793A1 (ru) 2004-10-28

Similar Documents

Publication Publication Date Title
LTC1436271I2 (lt) Fenilpiperazino dariniai, kaip serotonino grįžtamos absorbcijos inhibitoriai
HRP20050467A2 (en) Combination of beta-3-receptor agonist and a balanced dual reuptake inhibitor of serotonine and norepinephrine
NO20040933L (no) Nye gamma-sekretaseinhibitorer.
NO20034307D0 (no) Cyklopropylindol-derivater som selektive serotonin- gjenopptaksinhibitorer
ECSP045145A (es) Uso de inhibidores de la recaptacion de norepinefrina para el tratamiento del fallo cognitivo
UY28348A1 (es) Compuestos novedosos
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
BR0114903A (pt) 7-azaindóis, sua aplicação como inibidores da fosfodiesterase 4 e processos para a sua preparação
UY28360A1 (es) Nuevos compuestos
BRPI0112375B8 (pt) aplidinas como derivados antitumorais
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
BRPI0415390A (pt) compostos de pirazinona substituìda para o tratamento da inflamação
NO20065907L (no) Nye tetrahydropyridotiofener
BR0115301A (pt) Uso de um inibidor seletivo da recaptação de norepinefrina
MY142214A (en) Prophylactic or therapeutic agent for depression or anxiety disorder
AR038898A1 (es) Composiciones para el tratamiento del cabello
ATE345135T1 (de) Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen
CY1110796T1 (el) Παραγωγα μορφολινης ως αναστολεις επαναπροσληψης νορεπινεφρινης
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
AR030750A1 (es) 1-amino-alquilciclohexanos como agentes tripanocidas
ITMI20021328A1 (it) Nuove piperazine 1,4 - disostituite
ATE338046T1 (de) 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza- cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität
WO2005053663A3 (en) Norepinephrine reuptake inhibitors useful for treatment of cognitive failure
IL284547A (en) 3 balls with lighting and air conditioning